Ernexa Therapeutics (ERNAW) Asset Writedowns and Impairment (2010 - 2022)

Ernexa Therapeutics (ERNAW) has 12 years of Asset Writedowns and Impairment data on file, last reported at -$28000.0 in Q4 2022.

• Quarterly Asset Writedowns and Impairment changed N/A year-over-year to -$28000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2023 was -$28000.0 (down 100.47% YoY) and the FY2025 annual result came in at $33000.0, changed N/A from the prior year.
• Asset Writedowns and Impairment fell to -$28000.0 in Q4 2022, from $6.0 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $6.0 million in Q2 2022 to a low of -$28000.0 in Q4 2022.
• A 4-year average of $525416.7 and a median of $25500.0 in 2018 frame the typical range for Asset Writedowns and Impairment.
• The widest YoY moves for Asset Writedowns and Impairment: up 13700.0% in 2020, down 105.77% in 2020.
• Tracing ERNAW's Asset Writedowns and Impairment over 4 years: stood at $25000.0 in 2018, then jumped by 108.0% to $52000.0 in 2019, then sank by 105.77% to -$3000.0 in 2020, then slumped by 833.33% to -$28000.0 in 2022.
• The last three Asset Writedowns and Impairment figures came in at -$28000.0 (Q4 2022), $6.0 million (Q2 2022), and -$3000.0 (Q4 2020), per Business Quant data.